TSX Delisting Review - Thallion Pharmaceuticals Inc. (TLN)
11 Jul, 2012, 08:45 ET
TORONTO, July 11, 2012 /CNW/ - DELISTING REVIEW: Thallion Pharmaceuticals Inc. (the "Company") - TSX is reviewing the Common Shares (Symbol: TLN) of the Company with respect to meeting the continued listing requirements. The Company has been granted 120 days in which to regain compliance with these requirements, pursuant to the Remedial Review Process.
About TMX Group (TSX-X) TMX Group's key subsidiaries operate cash and derivative markets for multiple asset classes including equities, fixed income and energy. Toronto Stock Exchange, TSX Venture Exchange, TMX Select, Montreal Exchange, Canadian Derivatives Clearing Corporation, Natural Gas Exchange, Boston Options Exchange (BOX), Shorcan, Shorcan Energy Brokers, Equicom and other TMX Group companies provide listing markets, trading markets, clearing facilities, data products and other services to the global financial community. TMX Group is headquartered in Toronto and operates offices across Canada (Montreal, Calgary and Vancouver), in key U.S. markets (New York, Houston, Boston and Chicago) as well as in London, Beijing and Sydney. For more information about TMX Group, visit our website at www.tmx.com. Follow TMX Group on Twitter at http://twitter.com/tmxgroup.
For further information:
Corporate Communications, TMX Group Inc., Toll Free 1-888-873-8392, [email protected]
Share this article